Newsroom | 5800 results

ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, announced that beginning October 1, 2026, eligible Anthem® Blue Cross® and Blue Shield® members will be the first in the United States to receive insurance coverage under a medical policy for the PrecivityAD2® blood test. This policy expands patient access to an innovative blood-based diagnostic test that helps health care professionals evaluate adults exp...

LA JOLLA, Calif.--(BUSINESS WIRE)--Arialys Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of ANRE...

WESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, one of the largest ambulatory cloud EHR providers, announced that Joi Life Wellness, a neurology practice in Georgia specializing in cognitive disorders, is leveraging the AI Assistant for PRISMA to access and review patient records within approximately five minutes from multiple days. The AI-driven health information search engine supports faster clinical decision-making and accelerated care delivery. Neurology practices frequently manage p...

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growi...

TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven bios...

SAN FRANCISCO--(BUSINESS WIRE)--Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, and Modality.AI, a leader in AI-enabled multimodal clinical assessments, today announced a collaboration to explore how molecular biomarkers and objective digital assessments can be combined to improve the characterization of central nervous system (CNS) disorders. The collaboration brings together Amprion's expertise in detecting disease-specific misfo...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.T...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of June 30, 2026, and provided business updates. Cash Position as of June 30, 2026 GenSight Biologics’ cash and cash equivalents totaled €1.7 million as of June 30, 2026, compared t...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et du système nerveux central, publie aujourd’hui sa situation de trésorerie au 30 juin 2026, et fait un point sur son activité. Situation de trésorerie au 30 juin 2026 La trésorerie et les équivalents de trésorerie de Ge...

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a commercial-stage precision neurology company pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases such as Parkinson’s disease, today announced publication of an independent, investigator-initiated study in the journal Neurology and Therapy evaluating the Octave® Multiple Sclerosis Disease Activity (MSDA) Test in one of the most consequential judgment calls in MS care, whether a patient...